Gerald L. Ray & Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
$5.22M Hold
85,437
0.65% 38
2017
Q2
$5.22M Hold
85,437
0.67% 37
2017
Q1
$5.18M Buy
85,437
+613
+0.7% +$37.2K 0.71% 34
2016
Q4
$4.76M Buy
84,824
+2,096
+3% +$123K 0.69% 37
2016
Q3
$4.93M Sell
82,728
-1,033
-1% -$60.4K 0.74% 35
2016
Q2
$4.61M Buy
83,761
+241
+0.3% +$12.8K 0.74% 39
2016
Q1
$4.22M Buy
83,520
+714
+0.9% +$35K 0.68% 40
2015
Q4
$4.17M Buy
82,806
+1,083
+1% +$54.6K 0.66% 38
2015
Q3
$3.85M Sell
81,723
-52
-0.1% -$2.76K 0.64% 41
2015
Q2
$4.44M Sell
81,775
-571
-0.7% -$32K 0.68% 39
2015
Q1
$4.52M Buy
82,346
+88
+0.1% +$4.98K 0.68% 41
2014
Q4
$4.46M Sell
82,258
-100
-0.1% -$5.57K 0.69% 40
2014
Q3
$4.66M Sell
82,358
-352
-0.4% -$19.8K 0.76% 38
2014
Q2
$4.57M Buy
82,710
+685
+0.8% +$37.4K 0.78% 36
2014
Q1
$4.44M Buy
82,025
+5
+0% +$259 0.81% 36
2013
Q4
$3.92M Buy
82,020
+5
+0% +$229 0.74% 39
2013
Q3
$3.73M Buy
82,015
+5
+0% +$228 0.77% 38
2013
Q2
$3.63M Buy
+82,010
New +$3.66M 0.81% 40

Other funds holding MRK

Gerald L. Ray & Associates's MRK Position: Q3 2017 in Review

Gerald L. Ray & Associates held its Merck (MRK) position steady in Q3 2017 at 85,437 shares worth $5.22M. The position accounts for 0.65% of the portfolio, ranked #38.

Gerald L. Ray & Associates first reported a position in MRK in Q2 2013 and has held it in 18 quarters since. The position peaked at $5.22M in Q2 2017. 1,923 funds tracked by Wall St. Rank hold MRK as of Q3 2017.

  • Gerald L. Ray & Associates held 85,437 shares of Merck worth $5.22M as of Q3 2017.
  • Gerald L. Ray & Associates left its Merck share count unchanged in Q3 2017.
  • Merck made up 0.65% of Gerald L. Ray & Associates's portfolio in Q3 2017, its #38 holding.
  • Gerald L. Ray & Associates first reported a position in Merck in Q2 2013 and has held it in 18 quarters since.
  • Gerald L. Ray & Associates's Merck position peaked at $5.22M in Q2 2017.
  • 1,923 funds tracked by Wall St. Rank held Merck as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.